Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
BofA moves to No Rating on Sage Therapeutics after Biogen bid
09:29am, Monday, 13'th Jan 2025
Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
07:24am, Monday, 13'th Jan 2025
The biopharmaceutical company says its board of directors will now review and evaluate the offer from Biogen.
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
06:49pm, Friday, 10'th Jan 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicite
Biogen proposes to buy remaining stake in Sage in $442 million deal
06:37pm, Friday, 10'th Jan 2025
Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade.
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
08:00am, Wednesday, 08'th Jan 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
07:45am, Saturday, 04'th Jan 2025
Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in the
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
10:51am, Wednesday, 01'st Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Beaten Down Biogen Stock Looks Attractive At Current Levels
01:37pm, Monday, 30'th Dec 2024
The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. The company is executing a turnaround strategy that includes cost-cutting, pi
Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman
03:45pm, Monday, 23'rd Dec 2024
Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025.
Private Medicare plans must cover Biogen's ALS drug, US agency says
12:52pm, Thursday, 12'th Dec 2024
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen's amyotrophic lateral sclerosis drug Qalsody after finding instances of co
Analysts Predict These Will Be Next Year's Top 10 Stocks
08:00am, Wednesday, 11'th Dec 2024
Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock
09:35am, Tuesday, 10'th Dec 2024
Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
01:44pm, Monday, 09'th Dec 2024
Jefferies downgraded Biogen Inc BIIB, citing the company's tough setup.
Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript
12:15pm, Tuesday, 03'rd Dec 2024
Biogen Inc. (NASDAQ:BIIB ) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ET Company Participants Alisha Alaimo - President and Head of North America Michael Mc
Biogen expects steady growth for Alzheimer's drug Leqembi in near term
09:57am, Tuesday, 03'rd Dec 2024
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on Tue
